Immunterapi til patienter med malignt melanom og hjernemetastaser

Line Thing Simonsen; Anne Mette Sjørslev Schmidt; Trine Heide Øllegaard; Inge Marie Svane; Lars Bastholt; Adam Andrzej Luczak; Henrik Schmidt

Immunterapi til patienter med malignt melanom og hjernemetastaser

Translated title of the contribution: Immunotherapy for patients with malignant melanoma and brain metastases

Line Thing Simonsen, Anne Mette Sjørslev Schmidt, Trine Heide Øllegaard, Inge Marie Svane, Lars Bastholt, Adam Andrzej Luczak, Henrik Schmidt

Center for Cancer Immune Therapy (CCIT)

Abstract

Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

Translated title of the contribution	Immunotherapy for patients with malignant melanoma and brain metastases
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	181
Issue number	24
ISSN	0041-5782
Publication status	Published - 10 Jun 2019

Cite this

@article{a26f6e4dcc9d48ccbde89652f358286b,

title = "Immunterapi til patienter med malignt melanom og hjernemetastaser",

abstract = "Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.",

author = "Simonsen, \{Line Thing\} and Schmidt, \{Anne Mette Sj{\o}rslev\} and {\O}llegaard, \{Trine Heide\} and Svane, \{Inge Marie\} and Lars Bastholt and Luczak, \{Adam Andrzej\} and Henrik Schmidt",

year = "2019",

month = jun,

day = "10",

language = "Dansk",

volume = "181",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "24",

}

TY - JOUR

T1 - Immunterapi til patienter med malignt melanom og hjernemetastaser

AU - Simonsen, Line Thing

AU - Schmidt, Anne Mette Sjørslev

AU - Øllegaard, Trine Heide

AU - Svane, Inge Marie

AU - Bastholt, Lars

AU - Luczak, Adam Andrzej

AU - Schmidt, Henrik

PY - 2019/6/10

Y1 - 2019/6/10

N2 - Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

AB - Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

UR - https://www.scopus.com/pages/publications/85069267455

M3 - Tidsskriftartikel

C2 - 31267950

SN - 0041-5782

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 24

ER -

Immunterapi til patienter med malignt melanom og hjernemetastaser

Abstract

Other files and links

Fingerprint

Cite this